Inovio Pharmaceuticals (INO) Current Deferred Revenue (2010 - 2022)
Inovio Pharmaceuticals (INO) posted Current Deferred Revenue of $9.0 million for Q2 2022, up 58312.14% sequentially from $15378.0 in Q1 2022, and up 8131.27% YoY from $109128.0 in Q2 2021.
Inovio Pharmaceuticals (INO) Current Deferred Revenue (2010 - 2022) Analysis & Trends
Inovio Pharmaceuticals has reported Current Deferred Revenue for 13 years, with the latest figure at $9.0 million in Q2 2022.
- Quarterly Current Deferred Revenue rose 8131.27% year-over-year to $9.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $9.0 million (up 8131.27% YoY) and the FY2021 annual result came in at $21628.0, down 53.62% from the prior year.
- Current Deferred Revenue advanced to $9.0 million in Q2 2022 per INO's latest filing, from $15378.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $24.1 million in Q1 2018 and troughed at $14853.0 in Q2 2020.
- A 5-year average of $2.0 million and a median of $99232.0 in 2019 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2019 and 2022: Current Deferred Revenue plunged 99.54% in 2019, then surged 8131.27% in 2022.
- Over 5 years, Current Deferred Revenue stood at $223577.0 in 2018, then sank by 58.69% to $92353.0 in 2019, then tumbled by 49.51% to $46628.0 in 2020, then tumbled by 53.62% to $21628.0 in 2021, then jumped by 41432.36% to $9.0 million in 2022.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $9.0 million, $15378.0, and $21628.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 8.98 Mn |
| Mar 31, 2022 | 15,378.00 |
| Dec 31, 2021 | 21,628.00 |
| Sep 30, 2021 | 77,878.00 |
| Jun 30, 2021 | 109,128.00 |
| Mar 31, 2021 | 15,378.00 |
| Dec 31, 2020 | 46,628.00 |
| Sep 30, 2020 | 77,878.00 |
| Jun 30, 2020 | 14,853.00 |
| Mar 31, 2020 | 67,269.00 |
| Dec 31, 2019 | 92,353.00 |
| Sep 30, 2019 | 106,111.00 |
| Jun 30, 2019 | 120,694.00 |
| Mar 31, 2019 | 110,694.00 |
| Dec 31, 2018 | 223,577.00 |
| Sep 30, 2018 | 1.03 Mn |
| Jun 30, 2018 | 979,803.00 |
| Mar 31, 2018 | 24.09 Mn |
| Dec 31, 2017 | 1.18 Mn |
| Sep 30, 2017 | 179,523.00 |